SE9401709D0 - Improved alphavirus vectors for expression of heterologous DNA - Google Patents

Improved alphavirus vectors for expression of heterologous DNA

Info

Publication number
SE9401709D0
SE9401709D0 SE9401709A SE9401709A SE9401709D0 SE 9401709 D0 SE9401709 D0 SE 9401709D0 SE 9401709 A SE9401709 A SE 9401709A SE 9401709 A SE9401709 A SE 9401709A SE 9401709 D0 SE9401709 D0 SE 9401709D0
Authority
SE
Sweden
Prior art keywords
expression
alphavirus
heterologous dna
vectors
alphavirus vectors
Prior art date
Application number
SE9401709A
Other languages
English (en)
Swedish (sv)
Inventor
Mathilda Sjoeberg
Maarit Suomalainen
Henrik Garoff
Original Assignee
Mathilda Sjoeberg
Maarit Suomalainen
Henrik Garoff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mathilda Sjoeberg, Maarit Suomalainen, Henrik Garoff filed Critical Mathilda Sjoeberg
Priority to SE9401709A priority Critical patent/SE9401709D0/xx
Publication of SE9401709D0 publication Critical patent/SE9401709D0/xx
Priority to DE69535376T priority patent/DE69535376T2/de
Priority to CA002188421A priority patent/CA2188421A1/en
Priority to PCT/SE1995/000558 priority patent/WO1995031565A1/en
Priority to AT95920347T priority patent/ATE352633T1/de
Priority to AU25826/95A priority patent/AU698976B2/en
Priority to JP52958095A priority patent/JP3786956B2/ja
Priority to EP95920347A priority patent/EP0760000B1/en
Priority to US08/737,608 priority patent/US6224879B1/en
Priority to FI964577A priority patent/FI964577A/fi
Priority to US09/657,312 priority patent/US6692750B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
SE9401709A 1994-05-18 1994-05-18 Improved alphavirus vectors for expression of heterologous DNA SE9401709D0 (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE9401709A SE9401709D0 (sv) 1994-05-18 1994-05-18 Improved alphavirus vectors for expression of heterologous DNA
US08/737,608 US6224879B1 (en) 1994-05-18 1995-05-17 Alphavirus expression vector
AT95920347T ATE352633T1 (de) 1994-05-18 1995-05-17 Expressionsvektor des alphavirus
CA002188421A CA2188421A1 (en) 1994-05-18 1995-05-17 Alphavirus expression vector
PCT/SE1995/000558 WO1995031565A1 (en) 1994-05-18 1995-05-17 Alphavirus expression vector
DE69535376T DE69535376T2 (de) 1994-05-18 1995-05-17 Expressionsvektor des alphavirus
AU25826/95A AU698976B2 (en) 1994-05-18 1995-05-17 Alphavirus expression vector
JP52958095A JP3786956B2 (ja) 1994-05-18 1995-05-17 アルファウイルス発現ベクター
EP95920347A EP0760000B1 (en) 1994-05-18 1995-05-17 Alphavirus expression vector
FI964577A FI964577A (fi) 1994-05-18 1996-11-15 Alfavirusilmennysvektori
US09/657,312 US6692750B1 (en) 1994-05-18 2000-09-07 Alphavirus expression vector

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9401709A SE9401709D0 (sv) 1994-05-18 1994-05-18 Improved alphavirus vectors for expression of heterologous DNA

Publications (1)

Publication Number Publication Date
SE9401709D0 true SE9401709D0 (sv) 1994-05-18

Family

ID=20394041

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9401709A SE9401709D0 (sv) 1994-05-18 1994-05-18 Improved alphavirus vectors for expression of heterologous DNA

Country Status (10)

Country Link
US (2) US6224879B1 (ja)
EP (1) EP0760000B1 (ja)
JP (1) JP3786956B2 (ja)
AT (1) ATE352633T1 (ja)
AU (1) AU698976B2 (ja)
CA (1) CA2188421A1 (ja)
DE (1) DE69535376T2 (ja)
FI (1) FI964577A (ja)
SE (1) SE9401709D0 (ja)
WO (1) WO1995031565A1 (ja)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6465634B1 (en) 1996-04-05 2002-10-15 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
JP2001501483A (ja) * 1996-10-10 2001-02-06 ガロフ，ヘンリク アルファウイルス―レトロウイルスベクター
US5811407A (en) 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6432699B1 (en) 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
EP0981636B1 (en) 1997-05-13 2005-03-23 University Of North Carolina At Chapel Hill Lentivirus-based gene transfer vectors
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
ATE391726T1 (de) 1999-10-22 2008-04-15 Sanofi Pasteur Ltd Modifiziertes gp100 und dessen verwendung
WO2001085932A2 (en) 2000-05-10 2001-11-15 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
ES2312447T3 (es) 2000-05-31 2009-03-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento para la purificacion de particulas de replicon alfavirus.
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
US6982087B2 (en) 2000-09-07 2006-01-03 The University Of North Carolina At Chapel Hill Vectors derived from South African Arbovirus No. 86
CA2430947A1 (en) 2000-12-08 2002-06-13 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
CA2440890C (en) * 2001-03-27 2011-07-19 New York University Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors
US7045335B2 (en) 2001-09-06 2006-05-16 Alphavax, Inc. Alphavirus replicon vector systems
WO2003085087A2 (en) 2002-04-09 2003-10-16 Aventis Pasteur, Limited Modified cea nucleic acid and expression vectors
US6899507B2 (en) * 2002-02-08 2005-05-31 Asm Japan K.K. Semiconductor processing apparatus comprising chamber partitioned into reaction and transfer sections
EP1386926A1 (en) * 2002-07-29 2004-02-04 Bioxtal Methods for producing labelled recombinant polypeptides and uses thereof
JP4991108B2 (ja) * 2002-12-13 2012-08-01 アルファバックス，インコーポレイティド 多抗原性アルファウイルス・レプリコン粒子及び方法
WO2004055167A2 (en) * 2002-12-13 2004-07-01 Alphavax, Inc. Alphavirus particles and methods for preparation
WO2004063342A2 (en) * 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
EP1608762B1 (en) 2003-03-20 2014-01-08 Alphavax, Inc. Improved alphavirus replicons and helper constructs
AU2004257214B2 (en) * 2003-07-11 2010-04-22 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
US7910093B2 (en) 2003-08-19 2011-03-22 New York University Method for detecting cancer cells and monitoring cancer therapy
JP4668919B2 (ja) * 2003-10-08 2011-04-13 サノフィ パストゥール インコーポレイテッド 修飾ｃｅａ／ｂ７ベクター
JP2007535329A (ja) * 2004-04-29 2007-12-06 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 細胞接着性を増強する方法および組成物
CA2567254C (en) * 2004-05-18 2012-03-13 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
EP1773403B1 (en) 2004-07-09 2018-04-25 The University of North Carolina At Chapel Hill Alphavirus-based adjuvants
US8486420B2 (en) * 2005-02-15 2013-07-16 The University Of North Carolina At Chapel Hill Live virus vaccines
US7303898B2 (en) * 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
US20100233209A1 (en) * 2005-08-11 2010-09-16 Higgs Stephen T Chikungunya virus infectious clones and uses therefor
US20100322951A1 (en) * 2006-12-29 2010-12-23 Bacilligen, Inc. Replication-proficient dsRNA capsids and uses thereof
CA2689588C (en) 2007-06-21 2016-08-23 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
BRPI0913045A2 (pt) * 2008-05-23 2017-05-23 Fit Biotech Oy vetor de expressão codificador de alfa-vírus replicase e uso do mesmo como adjuvante imunológico
EP3443107A1 (en) 2016-04-13 2019-02-20 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
EP3526332B1 (en) 2016-10-17 2024-06-26 Janssen Pharmaceuticals, Inc. Recombinant virus replicon systems and uses thereof
JP2020500536A (ja) * 2016-12-05 2020-01-16 シンセティック ジェノミクス インコーポレーテッド 遺伝子発現増強のための組成物および方法
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
KR20200111729A (ko) 2018-01-19 2020-09-29 얀센 파마슈티칼즈, 인코포레이티드 재조합 레플리콘 시스템을 이용한 면역 반응 유도 및 증진

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
SE9003978D0 (sv) * 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
GB9406498D0 (en) 1994-03-31 1994-05-25 Smithkline Beecham Biolog Novel compounds

Also Published As

Publication number Publication date
JP3786956B2 (ja) 2006-06-21
AU698976B2 (en) 1998-11-12
JPH10500017A (ja) 1998-01-06
EP0760000B1 (en) 2007-01-24
DE69535376D1 (de) 2007-03-15
FI964577A0 (fi) 1996-11-15
ATE352633T1 (de) 2007-02-15
WO1995031565A1 (en) 1995-11-23
US6224879B1 (en) 2001-05-01
CA2188421A1 (en) 1995-11-23
FI964577A (fi) 1996-11-15
EP0760000A1 (en) 1997-03-05
AU2582695A (en) 1995-12-05
US6692750B1 (en) 2004-02-17
DE69535376T2 (de) 2007-11-08

Similar Documents

Publication Publication Date Title
SE9401709D0 (sv) Improved alphavirus vectors for expression of heterologous DNA
AU2155795A (en) Alphavirus cdna vectors
DE69637660D1 (de) Verfahren zür einführung und expression von genen in tierischen zellen
FR2681786B1 (ja)
BR0010725A (pt) Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc
AU2001254624A1 (en) Human coagulation factor vii variants
HK1024714A1 (en) Dumbbell expression constructs for gene therapy
BR9913331A (pt) Expressão e exportação de inibidores de angiogênese como imunofusinas
MY134810A (en) Targeted gene expression of thrombopoietein, dnase i and b-interferon
DE69928745D1 (de) Uracyl-phosphoribosyltransferase mutante
IL122120A (en) Recombinant mva virus containing a foreign gene inserted in a naturally occuring deletion within the genome
DE69518910D1 (de) Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle
DK1681355T3 (da) Sekvensspecifik DNA-rekombination i eukaryote celler
TR199802648A2 (xx) Gen tedavisi i�in n�klein asit yap�lar�.
EP0804613A4 (en) TUMOR SUPPRESSORGENES, PROTEINS CODED BY THEM AND THE USE OF SUCH GENES AND PROTEINS
DK0843731T3 (da) Adenovirusvektorer til genterapi
DK0596881T3 (da) Ekspression i ikke-tumurale humane lymofoblastoider med en integrativ vektor
DE3852006D1 (de) Expressionsvektor zur regulierbaren expression von fremdgenen in prokaryonten.
ATE162853T1 (de) Menschlicher rekombinanter plazentaler ribonuklease-inhibitor und verfahren zur herstellung
HUP0202722A2 (hu) Szekvencia-specifikus DNS-rekombináció eukarióta sejtekben
ATE59204T1 (de) Verfahren zum einbringen von klonierten amplifizierbaren genen in eukaryotische zellen und zur herstellung von proteinprodukten.
PL344766A1 (en) Recombined dna sequence, vector incorporating such recombined dna sequence, proteins obtained by expression of that recombined dna sequence and micro-organism's or plant's cell or their protoplasts transformed by that recombined dna sequence